{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:26:10Z","timestamp":1774293970028,"version":"3.50.1"},"reference-count":62,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2025,5,4]]},"DOI":"10.1080\/14737140.2025.2478891","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T05:34:56Z","timestamp":1741757696000},"page":"499-515","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["A nuanced review of neoadjuvant therapies in oral cancer"],"prefix":"10.1080","volume":"25","author":[{"given":"Akshat","family":"Malik","sequence":"first","affiliation":[{"name":"Max Super specialty Hospital","place":["New Delhi, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanishk","family":"Vishnoi","sequence":"additional","affiliation":[{"name":"Max Super specialty Hospital","place":["New Delhi, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanita","family":"Noronha","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute","place":["Mumbai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Prabhash","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute","place":["Mumbai, India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194967"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/app10113896"},{"key":"e_1_3_6_6_1","unstructured":"Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin - PubMed [Internet]. [cited 2024 Dec 29]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/4038469\/"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.01.013"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.146"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00179"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.8820"},{"key":"e_1_3_6_11_1","unstructured":"Citation for: phase III trial of docetaxel cisplatin 5\u2010fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome [Internet]. [cited 2024 Dec 31]. Available from: https:\/\/onlinelibrary.wiley.com\/action\/showCitFormats?doi=10.1002%2Fcac2.12136&mobileUi=0"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031317"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1456"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.123627"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e18073"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21984"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2014.07.015"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijmpo.ijmpo_185_16"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2022.1460"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071028"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070956"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106633"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11195582"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132818"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-509X.117024"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2022.1425"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-1768038"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33471"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33103"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21560"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5851.171548"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2015.10.004"},{"key":"e_1_3_6_33_1","unstructured":"Tables of possible side effects for commonly-used oncology drugs | protocol development | CTEP [Internet]. [cited 2025 Jan 17]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/sideeffects\/drugs.htm?utm_source=chatgpt.com"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113560"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.5500"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.4103\/2278-330X.195338"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2004.06.003"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30066-3"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8"},{"issue":"8","key":"e_1_3_6_41_1","first-page":"2220","article-title":"Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (illuminate trial)","volume":"109","author":"Huang Y","year":"2023","unstructured":"Huang Y, Sun J, Li J, et al. Neoadjuvant immunochemotherapy for locally advanced resectable oral squamous cell carcinoma: a prospective single-arm trial (illuminate trial). Int J Surg [Internet]. 2023 [cited 2025 Jan 3];109(8):2220\u20132227.","journal-title":"Int J Surg"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33080-8"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.6019"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2023.106479"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1189752"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27741"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.382"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.0425"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.05.007"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.24694"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.4170"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2289"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijom.2006.10.009"},{"key":"e_1_3_6_55_1","unstructured":"Study details | neoadjuvant tirellizumab combined with chemotherapy for early oral squamous cell Carcinoma(HNC-SYSU-004) | ClinicalTrials.Gov [Internet]. [Ava [cited 2025 Jan 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06130332"},{"key":"e_1_3_6_56_1","unstructured":"Study details | a prospective single-arm phase II clinical trial of tislelizumab combined with platinum doublet neoadjuvant therapy to improve mandibular preservation in resectable locally advanced oral squamous cell carcinoma. | ClinicalTrials.gov [Internet]. [Ava [cited 2025 Jan 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06130007"},{"key":"e_1_3_6_57_1","unstructured":"Study Details | TPExtreme Induced Chemotherapy Followed by Surgery and Radiotherapy in the Oral Carcinoma. | ClinicalTrials.gov [Internet]. [Ava [cited 2025 Jan 17]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05872880?term=NCT05872880&rank=1"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS6090"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13020303"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1089\/ten.tea.2024.0096"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41199-020-00053-7"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2017.11.007"},{"issue":"1","key":"e_1_3_6_63_1","first-page":"1","article-title":"Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients","volume":"23","author":"Zhang J","year":"2023","unstructured":"Zhang J, Wu Q, Yin W, et al. Development and validation of a radiopathomic model for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. BMC Cancer [Internet]. 2023 [cited 2025 Mar 6];23(1):1\u201312.","journal-title":"BMC Cancer"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.18383\/j.tom.2018.00038"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2025.2478891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T11:23:52Z","timestamp":1746185032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2025.2478891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,4]]}},"alternative-id":["10.1080\/14737140.2025.2478891"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2025.2478891","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}